secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001140361-24-046034
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Femasys Q3 2024 revenue up 127% to $555K; net loss widens to $5.4M
------------------------------------------------------------------

- Revenue $554,908 (+127% YoY); first U.S. and international FemaSeed sales in Q3.
- Net loss $5.4M ($0.24/share) vs $4.0M ($0.26/share) in Q3 2023.
- Cash $7.6M; expects runway into July 2025.
- Announced partnerships with Boston IVF and Spain distributors; Spain deals expected >$1.3M over next year.
- Received FDA clearance for FemChec, CE mark for FemVue MINI, and patent for FemBloc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036124046034/0001140361-24-046034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036124046034/ef20038399_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-046034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer